As the market for GLP-1 injections continues to grow, BD aims to ride that wave by providing drugmakers with its prefilled syringes. Biologic medications—including those blockbusters for diabetes and ...
After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...
The scientific-instrument company Waters will deepen its biological sciences footprint by merging with the biosciences and diagnostic solution business of Becton, Dickinson (BD). The companies value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback